ClinicalTrials.gg
AvailableNCT06149663Updated Jan 22, 2025

Intermediate-Size Expanded Access Protocol (EAP) for LP352

An expanded access record providing LP352 in Dravet Syndrome, Lennox Gastaut Syndrome and Developmental and Epileptic Encephalopathies, sponsored by Longboard Pharmaceuticals. Available at 22 sites in 2 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Longboard Pharmaceuticals (part of H. Lundbeck A/S) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Other kind
7 of 61
none open now
Registered
52nd of 61
by date
Lead sponsor
5 of 61
Longboard Pharmaceuticals

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is one of 7 of another kind, and was the 52nd registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

03

Conditions studied

  • Dravet Syndrome
  • Lennox Gastaut Syndrome
  • Developmental and Epileptic Encephalopathies

Keywords

  • CDKL5 deficiency disorder
  • developmental and epileptic encephalopathy
  • Dravet Syndrome
  • epilepsy
  • Lennox Gastaut Syndrome
  • treatment resistant epilepsy
  • tuberous sclerosis complex
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant and/or participant's legally authorized representative is willing and able to provide a written or assent form before participation in this EAP. An assent should be obtained from the patient, if possible. Assent must be obtained for adolescent EAP patients (\<18 years of age) as required by local regulations.
  2. Participant with DEE who has successfully completed an LP352 Clinical Trial.
  3. Participant currently has clinical benefit from LP352 treatment, as assessed by their Treating Physician.
  4. Participant currently tolerates LP352 treatment and has no safety issue which would prevent continued treatment.

Exclusion criteria

Exclusion Criteria:

  1. Participant was discontinued from an LP352 Clinical Trial for any reason.
  2. Any serious and/or unstable new medical condition, psychiatric disorder, or other conditions at the time of transition to this EAP that could interfere with patient's safety, obtaining , assent, or compliance to this EAP protocol, in the opinion of the Treating Physician.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • DrugBexicaserinStudies of BexicaserinBexicaserin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.

06

Where to request access

22 of 22 sites recruiting
  • Rancho Research Institute
    Downey, California 90242, United States
    Available
  • University of California Los Angeles (UCLA)
    Los Angeles, California 90095, United States
    Available
  • University of California Benioff Childrens Hospital
    San Francisco, California 94609, United States
    Available
  • Colorados Childrens Hospital
    Aurora, Colorado 80045, United States
    Available
  • Northwest Florida Clinical Research Group
    Gulf Breeze, Florida 32502, United States
    Available
  • Research Institute of Orlando
    Orlando, Florida 32792, United States
    Available
  • University of Southern Florida
    Tampa, Florida 33620, United States
    Available
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii 96817, United States
    Available
  • Northwestern Medicine Feinberg School of Medicine
    Chicago, Illinois 60611, United States
    Available
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
    Available
  • Corewell Health
    Grand Rapids, Michigan 49506, United States
    Available
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
    Available
  • New York University (NYU)
    New York, New York 10012, United States
    Available
  • Lenox Hill Hospital
    New York, New York 10075, United States
    Available
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Available
  • Providence Brain & Spine
    Portland, Oregon 97225, United States
    Available
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Available
  • Children's Neuro Consultants of Austin
    Austin, Texas 78757, United States
    Available
  • University of Utah
    Salt Lake City, Utah 84132, United States
    Available
  • Austin Hospital, Heidelberg
    Heidelberg, Melbourne 3084, Australia
    Available
  • Children's Health Queensland Hospital and Health Service,
    South Brisbane, Queensland 4101, Australia
    Available
  • Alfred Hospital
    Melbourne, 3004, Australia
    Available
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06149663
Responsible party
Sponsor
First posted
Nov 29, 2023
Last update
Jan 22, 2025

Study contacts

Longboard Study Contact
Contact
clinicalstudies@longboardpharma.com
858-999-8858
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion